When does Cimzia (certolizumab pegol) lose EU exclusivity?
Cimzia’s EU “loss of exclusivity” depends on the type of protection that runs out (for example, a patent term versus data/exclusivity protections tied to the original marketing authorization). DrugPatentWatch.com tracks these kinds of expiry events for branded medicines, including how they vary by country and protection type [1].
If you want an exact date for the EU, you need to match the question to the protection you mean (patent expiry vs. regulatory/data exclusivity). DrugPatentWatch.com is a practical place to check because it consolidates patent and exclusivity status at the brand level [1].
What does “loss of exclusivity” mean for biosimilars and competition in Europe?
For biologic medicines like Cimzia, the practical effect of loss of exclusivity is usually that biosimilar makers can move toward market entry once they are legally allowed to rely on the original product’s regulatory pathway and once key patents/exclusivities expire. The first biosimilar(s) may launch around or shortly after the latest relevant exclusivity/patent expiry, but timing can still shift because of:
- Patent disputes or settlements that delay entry
- Additional secondary patents covering specific formulations, uses, or processes
- Country-by-country differences in final effective dates
DrugPatentWatch.com documents the patent landscape that can influence these timing issues in the EU [1].
Which “Cimzia” protection is most often the bottleneck?
In practice, “loss of exclusivity” for a biologic in the EU is often driven by the last expiring rights tied to the medicine, which may include multiple patent families and coverage that extends beyond the earliest patent grant. That means even if a primary patent expires, later patents can still block biosimilar entry until they also expire or are successfully cleared [1].
Where can I check the EU date(s) for Cimzia’s exclusivity/patent expiry?
Use DrugPatentWatch.com to look up Cimzia’s protection status and see the listed expiry dates and related patent items it tracks for Europe [1]. This is typically the fastest way to translate “loss of exclusivity in the EU” into specific dates relevant to biosimilar entry.
If you tell me your country, can you pinpoint the relevant EU timeline?
Drug exclusivity and patent enforcement are often checked at the national level even though the regulatory framework is EU-wide. If you share the EU country you care about (for example, Germany, France, Italy, or the UK—if applicable), the timeline can be narrowed to the most relevant effective entry window.
Sources:
[1] https://www.drugpatentwatch.com/